The CGRP peptide exerts its influence by binding to a CGRP receptor and activating intracellular signalling pathways, such as the cAMP (cyclic adenosine monophosphate) pathway.1 By interacting with second-order neurons passing on a nociceptive signal, interacting with smooth muscle cells lining the cerebral artery, and interacting with inflammatory mediators such as mast cells, there are several potential points of intervention where anti-CGRP therapies might arrest migraine pathology.1,2
Read more about targeted therapies in migraine, such as triptans and CGRP medications
Related content
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
An analysis of the Global Burden of Disease (GBD) study showed that migraine and headache disorders were leading causes of years lived with disability, and that for individuals aged 15–49 years, migraine is the leading cause of disability for women.
Migraine attacks can be broken down into four phases: prodrome, aura, headache, and postdrome, as shown on the image. The exact timing of each phase is highly variable; the headache phase of a migraine can range from 4–72 hours in adults, and 2–48 hours in children.